Oncology Partnering Research Our Mission & Vision Biocartis’ vision is to enable personalized medicine for patients around the world through universal access to molecular testing. Our mission is to make molecular testing actionable, easy, fast and suitable for any lab. Meet Idylla IdyllaTM - A revolutionary, fully automated system that makes molecular testing easy, fast and suitable for any lab. Learn more Oncology Molecular biomarker results in only 3 hours for fast treatment decisions! THINK IDYLLA™ Learn more Oncology Research Biocartis encourages the research into new and emerging uses of different biomarkers. Learn more Partnering Biocartis believes in the power of collaboration and has partnership programs with pharmaceutical and diagnostic or biomarker companies Learn more Disease area oncology Lung Cancer Colorectal Cancer Melanoma Distributed by Biocartis APIS ESR1 Mutations Kit The APIS ESR1 Mutations Kit is an advanced qPCR assay for the sensitive and precise detection of mutations within the oestrogen receptor gene. The APIS ESR1 Mutations Kit is a qualitative test, detecting eleven ESR1 mutations across three exons: exon 5 (E380Q), exon 7 (S463P) and exon 8 (P535H, L536R, L536Q, L536H, L536P, Y537C, Y537S, Y537N and D538G). Read more APIS Breast Cancer Subtyping Kit The APIS Breast Cancer Subtyping Kit is a highly reproducible, RNA-based diagnostic workflow for detecting mRNA expression of standard biomarkers (ER, PR, HER2, Ki67) and novel proliferative biomarkers from pre-operative core-needle biopsy (CNB) or resected formalin-fixed paraffin-embedded (FFPE) breast tumour tissue. Read more Idylla ThyroidPrint® Assay First-in-class cartridge-based assay for risk stratification of indeterminate thyroid nodules. Read more Merlin™ Assay Merlin helps identify melanoma patients who have a low risk for nodal metastasis and may forgo the sentinel lymph node biopsy (SLNB). Read more HepatoPredict HepatoPredict employs a machine learning algorithm combing tumor gene expression with clinical variables to accurately identify hepatocellular carcinoma patients for liver transplantation. Read more
